胸腺肽α1对肝细胞癌根治性手术预后的影响

梁泳荣; 柯阳; 钟鉴宏; 郭哲; 姜经航; 向邦德

doi:10.3969/j.issn.1000-8179.20132118

胸腺肽α1对肝细胞癌根治性手术预后的影响

doi: 10.3969/j.issn.1000-8179.20132118

梁泳荣^{①, ②,},
柯阳^{①, ③},
钟鉴宏^①,
郭哲^①,
姜经航^①,
向邦德^①, ,

①.
广西医科大学附属肿瘤医院肝胆外科（南宁市 530021）
②.
钦州市第一人民医院肝胆外科
③.
昆明医科大学第二附属医院肝胆外科

基金项目:

国家科技重大专项课题项目 012ZX10002010001009

国家自然科学基金项目 81260331

详细信息

作者简介:
梁泳荣住院医师，医学硕士。研究方向为原发性肝癌的诊断与治疗。E-mail：liangyongrong1987@163.com

通讯作者:
向邦德 E-mail: xiangbangde@163.com.

计量
- 文章访问数: 17
- HTML全文浏览量: 24
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2013-12-12
- 修回日期: 2014-05-02
- 刊出日期: 2020-12-31

Thymosin alpha 1 for patients with hepatocellular carcinoma after radical hepatectomy

LIANG Yongrong^{①, ②
,},
Yang KE^{①, ③},
ZHONG Jianhong^①,
GUO Zhe^①,
JIANG Jinghang^①,
XIANG Bangde^{①
, ,}

①.
Department of Hepatobiliary Surgery, Tumor Hospital of Guangxi Medical University, Nanning 530021, China
②.
Department of Hepatobiliary Surgery, Qinzhou First People's Hospital, Qinzhou 535000, China
③.
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

More Information

Corresponding author: Bangde XIANG; E-mail: xiangbangde@163.com.

摘要

摘要: 目的探讨胸腺肽α1（Thymosin alpha 1，Tα1）对肝细胞癌（hepatocellular carcinoma，HCC）患者根治性手术预后的影响。方法回顾性分析本院2007年1月至2012年12月558例HCC根治性手术后患者，分为Tα1治疗组146例和空白对照组412例，经倾向性评分匹配后，比较两组术后肝功能恢复情况、无瘤生存率和总生存率。结果两组患者共106对匹配成功，中位随访时间为22个月，治疗组较对照组术后TBIL、ALB、ALT、PT等肝功能指标明显改善（P < 0.05）。治疗组和对照组术后1、2、3年无瘤生存率分别为79.7%、70.8%、67.3%和69.9%、61.5%、51.6%（P=0.019）；总生存率分别为87.2%、82.0%、68.4%和78.2%、64.2%、49.7%（P=0.011）。结论 HCC根治术后应用Tα1治疗能有效改善患者术后肝功能，显著提高患者无瘤生存率和总生存率。
- 肝细胞癌 /
- 总生存率 /
- 倾向性评分匹配法 /
- 无瘤生存率 /
- 胸腺肽α1
Abstract: Objective The effect of thymosin alpha 1 (T α 1) on patients with hepatocellular carcinoma (HCC) after radical hepatectomy was assessed. Methods A total of 558 HCC patients treated by radical hepatectomy were retrospectively collected. Patients in the treatment group (n=146) received postoperative Tα1 therapy, whereas patients in the control group (n=412) did not. Propensity scale matching was conducted to improve the balance between the two groups. Changes in liver function, recurrence-free survival rates, and overall survival rates were compared between the two groups. Results Postoperative liver function (i.e., TBIL, ALB, ALT, and PT) in the treatment group was significantly better than that in the control group (P < 0.05). The one-, two-, and three-year recurrence-free survival rates and overall survival rates in the treatment group were significantly higher than those in the control group (P=0.019 and P=0.011, respectively). Conclusion Postoperative Tα1 therapy can improve postoperative liver function, thus significantly prolonging recurrence-free survival and overall survival.
- hepatocellular carcinoma /
- overall survival rate /
- propensity score matching /
- recurrence-free survival rate /
- thymosin alpha 1

HTML全文

图 1 治疗组和对照组累积无瘤生存率的比较

Figure 1. Comparison of cumulative recurrence-free survival rates between the treatment group and the control group after operation

下载: 全尺寸图片幻灯片

图 2 治疗组和对照组累积生存率的比较

Figure 2. Comparison of cumulative survival rates between the treatment group and the control group after operation

下载: 全尺寸图片幻灯片

表 1 经PSM匹配前后治疗组和对照组的基线资料

Table 1. Baseline characteristics of the treatment and control groups

表 2 治疗组与对照组肝功能变化的比较

Table 2. Comparison of liver function between the treatment group and the control group after operation

参考文献(14)

[1]	Forner A, JM Llovet, J Bruix. Hepatocellular carcinoma[J]. The Lan cet, 2012, 379(9822):1245-1255. https://www.mayoclinic.org/diseases-conditions/hepatocellular-carcinoma/cdc-20354552
[2]	柯阳, 钟鉴宏, 游雪梅, 等.抗病毒治疗对乙型肝炎病毒相关性肝细胞癌患者根治性术后的影响[J].中国肿瘤临床, 2013(19):1184-1188. doi: 10.3969/j.issn.1000-8179.20131131 Ke Y, Zhong JH, You XM, et al. Antiviral, therapy for hepatitis B vi rus-related hepatocellular carcinoma after radical hepatectomy[J]. Chin J Clin Oncol, 2013(19):1184-1188. doi: 10.3969/j.issn.1000-8179.20131131
[3]	郑江华, 王广义.肝癌术后转移复发相关因素的研究进展[J].实用医学杂志, 2010, 26 (12):2239-2241. doi: 10.3969/j.issn.1006-5725.2010.12.080 Zheng JH, Wang GY. Research progression of factors related with postoperative transfer and recurrence in liver cancer[J]. The Journal of Practical Medicine, 2010, 26(12):2239-2241. doi: 10.3969/j.issn.1006-5725.2010.12.080
[4]	黎乐群, 苏智雄, 彭民浩, 等.手术打击对原发性肝癌病人术后免疫功能影响的研究[J].中华肝胆外科杂志, 2004, 10(6):420-421. doi: 10.3760/cma.j.issn.1007-8118.2004.06.022 Li LQ, Su LQ, Su ZX, et al. The immune functional affection to Primary liver cancer patients after Surgical strike[J]. Chinese Jour nal of Hepatobiltary Surgery, 2004, 10(6):420-421. doi: 10.3760/cma.j.issn.1007-8118.2004.06.022
[5]	Zhong JH, Ma L, Wu LC, et al. Adoptive immunotherapy for post operative hepatocellular carcinoma: a systematic review[J]. Int J Clin Pract, 2012, 66(1):21-27. doi: 10.1111/j.1742-1241.2011.02814.x
[6]	Matteucci C, Minutolo A, Sinibaldi-Vallebona P, et al. Transcrip tion profile of human lymphocytes following in vitro treatment with thymosin alpha-1[J]. Ann N Y Acad Sci, 2010, 1194:6-19. doi: 10.1111/j.1749-6632.2010.05484.x
[7]	程树群, 吴孟超, 陈汉, 等.胸腺肽α1对原发性肝癌术后复发的影响.中华肝胆外科杂志, 2004, 10(9):592-593. doi: 10.3760/cma.j.issn.1007-8118.2004.09.006 Cheng SQ, Wu MC, Chen H, et al. Anti-recurrence effects of thy mosin α1 in patients with primary liver cancer after hepatectomy[J]. Chinese Journal of Hepatobiltary Surgery, 2004, 10(9):592-593. doi: 10.3760/cma.j.issn.1007-8118.2004.09.006
[8]	邱福南, 王耀东, 田毅峰, 等.胸腺肽α1治疗对HBsAg阳性肝癌患者根治术后复发和预后的影响[J].中国综合临床, 2010, 26(4): 349-351. doi: 10.3760/cma.j.issn.1008-6315.2010.04.006 Qiu FN, Wang YD, Tian YF, et al. Efficacy of anti-biral therapy using thymosin1 in HBsAg positive hepatocellular carcinoma after hepatectomy[J]. Clinical Medicine of China, 2010, 26(4):349-351. doi: 10.3760/cma.j.issn.1008-6315.2010.04.006
[9]	Zhong JH, Ke Y, Gong WF, et al. Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma[J]. Ann Surg, 2013. [Epub ahead of print]. http://cn.bing.com/academic/profile?id=87ee7087c146020c41d886b7ed20e479&encoded=0&v=paper_preview&mkt=zh-cn
[10]	马良, 钟鉴宏, 黎乐群, 等.肝动脉化疗栓塞在肝细胞性肝癌切除术后应用的系统评价[J].中国癌症防治杂志, 2011, 3 (1):74-81. doi: 10.3969/j.issn.1674-5671.2011.01.21 Ma L, Zhong JH, Li LQ, et al. Postoperative transarterial chemoem bolization on patients with hepatocellular carcinoma:a systematic re view[J]. Chinese Jouranl of Oncology Prevention and treatment, 2011, 3(1):74-81. doi: 10.3969/j.issn.1674-5671.2011.01.21
[11]	Zhong JH, Li H, Li LQ, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma:a systematic review of randomized trials[J]. Eur J Surg Oncol, 2012, 38(4):286-295. doi: 10.1016/j.ejso.2012.01.006
[12]	Zhong JH, Li le Q, Wu LC, et al. Lamivudine with or without adefo vir dipivoxil for postoperative hepatocellular carcinoma[J]. Co chrane Database Syst Rev, 2011, 7(12):CD008713. doi: 10.1002/14651858.CD008713.pub2/abstract
[13]	Garaci E, Pica F, Serafino A, et al. Thymosin α1 and cancer: action on immune effector and tumor target cells[J]. Ann N Y Acad Sci, 2012, 1269:26-33. doi: 10.1111/j.1749-6632.2012.06697.x
[14]	黎乐群, 彭涛.复发性肝细胞癌的细胞克隆来源及其与复发时间的关系[J].中华肝胆外科杂志, 1999, 5(1):11. Li LQ, Peng T. Relationship between Cells cloned source and recur rence time inRHCC[J]. Chinese Journal of Hepatobiltary Surgery, 1999, 5(1):11.